CJC-1295 w/DAC (5mg)

4.9 stars

$45.00

Purchase this product now and earn 45 Points!
Category:

Size Options: 5mg Composition: Fragment 176-191 Form: Lyophilized Powder Purity: >99% Product Code: P-FRAG176-191

Enjoy Complimentary Shipping on Orders Over $200

Receive a Free 30ml Bac Water with Orders Over $200

Discounts Available for Larger Quantities

 

Description

CJC-1295 w/DAC (5mg) 

CJC-1295 is a peptide with potential similarities to GHRH, with the ability to potentially enhance growth hormone levels. DAC, a biochemical complex, is believed to play a crucial role in extending the peptide’s lifespan. Researchers have conducted studies on the combined effects of CJC-1295 and Ipamorelin to explore their synergistic potential. CJC-1295 is a synthetic analog consisting of 29 amino acids, mimicking growth hormone-releasing hormone (GHRH).

Researchers suggest that the hypothalamus is responsible for producing Growth Hormone-Releasing Hormone (GHRH), which may stimulate the synthesis and release of Growth Hormone (GH). The production of GHRH appears to be influenced by factors like metabolic status, gender, and age. GHRH is closely associated with functions related to sleep regulation and appetite control. Furthermore, the GH influenced by GHRH plays a crucial role in metabolism by promoting protein synthesis and maintaining normal blood glucose levels. It also has growth-promoting properties by stimulating various tissues, including the liver, to release growth factors that contribute to bone growth. Dysfunctions in GHRH can potentially lead to abnormal growth patterns.

Overview

CJC-1295 goes by several names, including CJC-1295, CJC-1295 with DAC, DAC:GRF, long-acting GHRH analog, and synthetic GHRH analog. This peptide, regarded as a growth hormone-releasing factor, has garnered attention for its potential roles:

  • Fat Reduction: CJC-1295 has been investigated for its ability to reduce fat mass by utilizing stored fat as an energy source. This process may contribute to an increase in muscle mass through enhanced protein synthesis.
  • Bone Health: Growth hormone is known to support bone growth and overall joint and connective tissue health. CJC-1295 peptide shows promise in potentially improving bone mass and reducing the risk of injuries.
  • Sleep Regulation: Research suggests that GHRH plays a role in regulating sleep patterns. Analogous peptides like CJC-1295 may extend this potential in assisting with normalized sleep patterns.

Research and Clinical Studies

CJC-1295 DAC Peptide Mechanism of Action

In 2006, researchers conducted two clinical studies to explore the mechanism of action of CJC-1295, involving subjects aged 21-61 years. In the first study, participants were administered varying concentrations of CJC-1295 or a placebo. In the second study, CJC-1295 was given two or three times weekly. Results indicated that CJC-1295 administration led to increased levels of GH (growth hormone) and IGF-I (Insulin-like growth factor 1) in the subjects.

Another study in 2006 examined GH pulsatility after a single dose of CJC-1295. It revealed a significant 50% increase in GH secretion and IGF-I levels following a single administration of CJC-1295.

Further animal studies were conducted to assess CJC-1295’s potential. One study, using mice, suggested that daily CJC-1295 treatment could potentially normalize growth. Additionally, CJC-1295 administered every 2 or 3 days produced intermediate results, suggesting a potential interval-dependent action.

CJC-1295 DAC Peptide Half-life

CJC-1295 employs a technology called Drug Affinity Complex (DAC) to extend its half-life. Unlike GHRH, which has a half-life of approximately 7 minutes, CJC-1295 is reported to have a longer half-life of 6-8 days due to the DAC technology.

CJC-1295 DAC Peptide Ancillary Studies

In 2005, a study commenced to investigate CJC-1295’s mechanism of action in individuals with HIV-associated visceral obesity. However, recruitment for this study was terminated, and no related results were published.

A Norwegian study in 2009 analyzed a compound to determine if it contained prohibited substances. This compound was identified as CJC-1295 by researchers at the Norwegian Doping Control Laboratory and School of Pharmacy. Their published findings concluded that “CJC-1295 is a releasing factor for growth hormone.”

 

CAS Number
PubChem CID
Molecular Weight
Molecular Formula
Synonyms
Storage (Lyophilized) At 39 Fahrenheit: 2 years At -4 Fahrenheit: 3 years

CJC-1295 w/DAC (5mg) 

CJC-1295 is a peptide with potential similarities to GHRH, with the ability to potentially enhance growth hormone levels. DAC, a biochemical complex, is believed to play a crucial role in extending the peptide’s lifespan. Researchers have conducted studies on the combined effects of CJC-1295 and Ipamorelin to explore their synergistic potential. CJC-1295 is a synthetic analog consisting of 29 amino acids, mimicking growth hormone-releasing hormone (GHRH).

Researchers suggest that the hypothalamus is responsible for producing Growth Hormone-Releasing Hormone (GHRH), which may stimulate the synthesis and release of Growth Hormone (GH). The production of GHRH appears to be influenced by factors like metabolic status, gender, and age. GHRH is closely associated with functions related to sleep regulation and appetite control. Furthermore, the GH influenced by GHRH plays a crucial role in metabolism by promoting protein synthesis and maintaining normal blood glucose levels. It also has growth-promoting properties by stimulating various tissues, including the liver, to release growth factors that contribute to bone growth. Dysfunctions in GHRH can potentially lead to abnormal growth patterns.

Overview

CJC-1295 goes by several names, including CJC-1295, CJC-1295 with DAC, DAC:GRF, long-acting GHRH analog, and synthetic GHRH analog. This peptide, regarded as a growth hormone-releasing factor, has garnered attention for its potential roles:

  • Fat Reduction: CJC-1295 has been investigated for its ability to reduce fat mass by utilizing stored fat as an energy source. This process may contribute to an increase in muscle mass through enhanced protein synthesis.
  • Bone Health: Growth hormone is known to support bone growth and overall joint and connective tissue health. CJC-1295 peptide shows promise in potentially improving bone mass and reducing the risk of injuries.
  • Sleep Regulation: Research suggests that GHRH plays a role in regulating sleep patterns. Analogous peptides like CJC-1295 may extend this potential in assisting with normalized sleep patterns.

Research and Clinical Studies

CJC-1295 DAC Peptide Mechanism of Action

In 2006, researchers conducted two clinical studies to explore the mechanism of action of CJC-1295, involving subjects aged 21-61 years. In the first study, participants were administered varying concentrations of CJC-1295 or a placebo. In the second study, CJC-1295 was given two or three times weekly. Results indicated that CJC-1295 administration led to increased levels of GH (growth hormone) and IGF-I (Insulin-like growth factor 1) in the subjects.

Another study in 2006 examined GH pulsatility after a single dose of CJC-1295. It revealed a significant 50% increase in GH secretion and IGF-I levels following a single administration of CJC-1295.

Further animal studies were conducted to assess CJC-1295’s potential. One study, using mice, suggested that daily CJC-1295 treatment could potentially normalize growth. Additionally, CJC-1295 administered every 2 or 3 days produced intermediate results, suggesting a potential interval-dependent action.

CJC-1295 DAC Peptide Half-life

CJC-1295 employs a technology called Drug Affinity Complex (DAC) to extend its half-life. Unlike GHRH, which has a half-life of approximately 7 minutes, CJC-1295 is reported to have a longer half-life of 6-8 days due to the DAC technology.

CJC-1295 DAC Peptide Ancillary Studies

In 2005, a study commenced to investigate CJC-1295’s mechanism of action in individuals with HIV-associated visceral obesity. However, recruitment for this study was terminated, and no related results were published.

A Norwegian study in 2009 analyzed a compound to determine if it contained prohibited substances. This compound was identified as CJC-1295 by researchers at the Norwegian Doping Control Laboratory and School of Pharmacy. Their published findings concluded that “CJC-1295 is a releasing factor for growth hormone.”

 

CAS Number 
PubChem CID 
Molecular Weight 
Molecular Formula 
Synonyms 
Storage (Lyophilized)

At 39 Fahrenheit: 2 years

At -4 Fahrenheit: 3 years

Related products